Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jconrel.2015.09.066 http://scihub22266oqcxt.onion/10.1016/j.jconrel.2015.09.066 C4665980!4665980 !26476177     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26476177 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Control+Release 2015 ; 218 (ä): 94-113 Nephropedia Template TP {{tp|p=26476177 |t=2015. Technologies for controlled, local delivery of siRNA |pdf=|usr=}}{{26476177 }} gab.com Text Technologies for controlled, local delivery of siRNA JO: J Control Release http://www.kidney.de/pget.php?&tw=1&pmid=26476177 #FOAvip The discovery of RNAi in the late 1990s unlocked a new realm of therapeutic possibilities by enabling potent and specific silencing of theoretically any desired genetic target. Better elucidation of the mechanism of action, the impact of chemical modifications that stabilize and reduce nonspecific effects of siRNA molecules, and the key design considerations for effective delivery systems has spurred progress toward developing clinically-successful siRNA therapies. A logical aim for initial siRNA translation is local therapies, as delivering siRNA directly to its site of action helps to ensure that a sufficient dose reaches the target tissue, lessens the potential for off-target side effects, and circumvents the substantial systemic delivery barriers. While locally injected or topically applied siRNA has progressed into numerous clinical trials, an enormous opportunity exists to develop sustained-release, local delivery systems that enable both spatial and temporal control of gene silencing. This review focuses on material platforms that establish both localized and controlled gene silencing, with emphasis on the systems that show most promise for clinical translation. Twit Text FOAVip Technologies for controlled, local delivery of siRNA ????J Control Release http://www.kidney.de/pget.php?&tw=1&pmid=26476177 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26476177 #FOAvip English Wikipedia <ref>{{Cite pmid|26476177 }}</ref> Technologies for controlled, local delivery of siRNA #MMPMID26476177 Sarett SM ; Nelson CE ; Duvall CL J Control Release 2015[Nov]; 218 (ä): 94-113 PMID26476177 show ga The discovery of RNAi in the late 1990s unlocked a new realm of therapeutic possibilities by enabling potent and specific silencing of theoretically any desired genetic target. Better elucidation of the mechanism of action, the impact of chemical modifications that stabilize and reduce nonspecific effects of siRNA molecules, and the key design considerations for effective delivery systems has spurred progress toward developing clinically-successful siRNA therapies. A logical aim for initial siRNA translation is local therapies, as delivering siRNA directly to its site of action helps to ensure that a sufficient dose reaches the target tissue, lessens the potential for off-target side effects, and circumvents the substantial systemic delivery barriers. While locally injected or topically applied siRNA has progressed into numerous clinical trials, an enormous opportunity exists to develop sustained-release, local delivery systems that enable both spatial and temporal control of gene silencing. This review focuses on material platforms that establish both localized and controlled gene silencing, with emphasis on the systems that show most promise for clinical translation. |Gene Silencing [MESH] |RNA, Small Interfering/*administration & dosage/therapeutic use [MESH]Technologies for controlled, local delivery of siRNA (epmc).pdf DeepDyve Pubget Overpricing